The immunotherapeutic agents covered in this module are summarized here.
Topics Covered:
Status of immunotherapeutic agents in oncology
Status of immunotherapeutic agents in oncology
This module discusses various clinical indications for which immunotherapeutic agents have been FDA approved, and highlights additional immunotherapeutic agents that are currently under investigation for these malignancies. By the time this module is published, the status of key agents likely will have changed and new agents may have emerged because the field of immuno-oncology is rapidly evolving. The Table below summarizes the status for select immunotherapeutic agents as of January 2017; it is intended to provide a snapshot of key agents, rather than a comprehensive listing, to illustrate the important role of immunotherapy in the treatment of cancer.
Table 1. Immunotherapeutic Agents for Cancer Treatment
Note: Please scroll horizontally to see all of the table content.
|
Agent
|
Brand name, Company
|
Type of Therapy
|
Target
|
FDA-approved Uses
|
Select Investigational Uses
|
|
Trastuzumab
|
Herceptin, Genentech
|
Monoclonal antibody
|
HER-2
|
Breast cancer; Gastric cancer
|
|
|
Ado-trastuzumab emtansine
|
Kadcyla, Genentech
|
ADC
|
HER-2
|
Breast cancer
|
Gastric cancer
|
|
Pertuzumab
|
Perjeta, Genentech
|
Monoclonal antibody
|
HER-2
|
Breast cancer
|
Gastric cancer
|
|
Glembatumumab vedotin
|
--
|
ADC
|
NMB
|
--
|
Breast cancer
|
|
Pembrolizumab
|
Keytruda, Merck
|
Monoclonal antibody; Checkpoint inhibitor
|
PD-1
|
Melanoma; NSCLC; SCCHN
|
Breast cancer; Colorectal cancer; Gastric cancer; Cervical cancer; NHL; CHL; ALCL; Multiple myeloma
|
|
Nivolumab
|
Opdivo, Bristol-Myers Squibb
|
Monoclonal antibody; Checkpoint inhibitor
|
PD-1
|
Melanoma; NSCLC; Kidney cancer; CHL
|
Breast cancer; Colorectal cancer; Cervical cancer; NHL; Multiple myeloma
|
|
Atezolizumab
|
Tecentriq, Genentech
|
Monoclonal antibody; Checkpoint inhibitor
|
PD-L1
|
NSCLC; Bladder cancer
|
Breast cancer; Melanoma; Colorectal cancer; NSCLC; Multiple myeloma
|
|
Avelumab
|
--
|
Monoclonal antibody; Checkpoint inhibitor
|
PD-L1
|
--
|
Gastric cancer; NSCLC; CHL
|
|
Durvalumab
|
MEDI4736, AstraZeneca
|
Monoclonal antibody; Checkpoint inhibitor
|
PD-L1
|
--
|
Melanoma; Colorectal cancer; Bladder cancer; Cervical cancer; Multiple myeloma
|
|
Margetuximab
|
--
|
Monoclonal antibody
|
HER2/neu
|
--
|
Breast cancer
|
|
Peginterferon alfa-2b
|
Sylatron, Schering
|
Cytokine
|
|
Melanoma
|
|
|
Ipilimumab
|
Yervoy, Bristol-Myers Squibb
|
Monoclonal antibody; Checkpoint inhibitor
|
CTLA-4
|
Melanoma
|
Colorectal cancer; Cervical cancer; CHL
|
|
Tremelimumab
|
--
|
Monoclonal antibody; Checkpoint inhibitor
|
CTLA-4
|
--
|
Colorectal cancer; Cervical cancer
|
|
Talimogene laherparepvec
|
Imlygic, Amgen
|
Oncolytic virus
|
|
Melanoma
|
|
|
Seviprotimut-L
|
--
|
Vaccine
|
|
--
|
Melanoma
|
|
Cetuximab
|
Erbitux, Eli Lilly
|
Monoclonal antibody
|
EGFR
|
Colorectal cancer; SCCHN
|
|
|
Bevacizumab
|
Avastin, Genentech
|
Monoclonal antibody
|
VEGF
|
Colorectal cancer; NSCLC; Kidney cancer; Cervical cancer; Glioblastoma;
Ovarian epithelial, fallopian tube, or primary peritoneal cancer
|
|
|
Panitumumab
|
Vectibix, Amgen
|
Monoclonal antibody
|
EGFR
|
Colorectal cancer
|
|
|
Ramucirumab
|
Cyramza, Eli Lilly
|
Monoclonal antibody
|
VEGFR-2
|
Colorectal cancer; Gastric cancer; NSCLC
|
|
|
Varlilumab
|
--
|
Monoclonal antibody
|
CD27
|
--
|
Colorectal cancer
|
|
PGG beta-glucan
|
Imprime PGG, Biothera
|
Vaccine
|
|
--
|
Colorectal cancer
|
|
Sipuleucel-T
|
Provenge, Dendreon
|
Vaccine
|
|
Prostate cancer
|
|
|
Rilimogene galvacirepvec/ rilimogene glafolivec
|
Prostvac, Bavarian Nordic
|
Vaccine
|
|
--
|
Prostate cancer
|
|
HPV quadrivalent (Types 6, 11, 16, and 18) vaccine, recombinant
|
Gardasil, Merck
|
Vaccine
|
|
Prevention of cervical cancer and other HPV-associated cancers
|
|
|
HPV 9-valent vaccine, recombinant
|
Gardasil 9, Merck
|
Vaccine
|
|
Prevention of cervical cancer and other HPV-associated cancers
|
|
|
HPV bivalent (types 16 and 18) vaccine, recombinant
|
Cervarix, GlaxoSmithKline
|
Vaccine
|
|
Prevention of cervical cancer and other HPV-associated cancers
|
|
|
Tisotumab vedotin
|
HuMax-TF-ADC, Genmab
|
ADC
|
Tissue Factor
|
--
|
Cervical cancer
|
|
Sacituzumab govitecan
|
IMMU-132, Immunomedics
|
ADC
|
Trop-2
|
--
|
Cervical cancer; Breast cancer
|
|
Rituximab
|
Rituxan, Genentech/Biogen
|
Monoclonal antibody
|
CD20
|
NHL; CLL
|
|
|
Ibritumomab tiuxetan
|
Zevalin, Spectrum
|
Radioimmunotherapy
|
CD20
|
NHL
|
|
|
Obinutuzumab
|
Gazyva, Genentech
|
Monoclonal antibody
|
CD20
|
NHL; CLL
|
|
|
Alemtuzumab
|
Campath, Genzyme
|
Monoclonal antibody
|
CD52
|
CLL
|
|
|
Ofatumumab
|
Arzerra, Novartis
|
Monoclonal antibody
|
CD20
|
CLL
|
|
|
Epacadostat
|
INCB024360, InCyte
|
Small molecule
|
IDO
|
--
|
NHL
|
|
Urelumab
|
--
|
Monoclonal antibody
|
CD37
|
--
|
NHL
|
|
Brentuximab vedotin
|
Adcetris, Seattle Genetics
|
ADC
|
CD30
|
CHL; ALCL
|
|
|
|
|
CAR therapies
|
CD19
|
|
CHL
|
|
Blinatumomab
|
Blincyto, Amgen
|
Monoclonal antibody
|
CD19, CD3
|
ALL
|
|
|
Inotuzumab ozogamicin
|
CMC-544, Pfizer
|
ADC
|
CD22
|
--
|
ALL
|
|
MEDI-570
|
--
|
Monoclonal antibody
|
ICOS
|
--
|
ALCL
|
|
Daratumumab
|
Darzalex, Janssen
|
Monoclonal antibody
|
CD38
|
Multiple myeloma
|
|
|
Elotuzumab
|
Empliciti, Bristol-Myers Squibb
|
Monoclonal antibody
|
SLAMF7
|
Multiple myeloma
|
|
|
Pidilizumab
|
--
|
Monoclonal antibody
|
PD-1
|
--
|
Multiple myeloma
|
|
ALT-803
|
--
|
Superagonist complex
|
IL-15
|
|
Multiple myeloma
|
ADC—antibody-drug conjugate; ALCL—anaplastic large cell lymphoma; ALL—acute lymphoblastic leukemia; CLH—classical Hodgkin lymphoma; CLL—chronic lymphocytic leukemia; HPV—human papillomavirus; ICOS—inducible T cell costimulator; IDO—indoleamine-2,3-dioxygenase; NHL—non-Hodgkin lymphoma; SCCHN—squamous cell carcinoma of the head and neck; SLAMF7—signaling lymphocytic activation molecule F7
Thank you for participating in this module. Click below to download the certificate.